Have a personal or library account? Click to login
Role of vascular endothelial growth factor receptor in the pro-proliferation activity of CD40-CD40L in AGS gastric cancer cells Cover

Role of vascular endothelial growth factor receptor in the pro-proliferation activity of CD40-CD40L in AGS gastric cancer cells

Open Access
|Apr 2018

References

  1. 1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.10.3322/CA.2007.001018287387
  2. 2. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer. 2008; 122:2286-93.10.1002/ijc.2339218224687
  3. 3. Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett. 2008; 266:99-115.10.1016/j.canlet.2008.02.05318381231
  4. 4. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/ CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004; 22:307-328.10.1146/annurev.immunol.22.012703.10453315032580
  5. 5. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res. 2007; 13: 1083-8.10.1158/1078-0432.CCR-06-189317317815
  6. 6. Schonbeck U, Libby P. The CD40/CD154 receptor/ ligand dyad. Cell Mol Life Sci. 2001; 58:4-43.10.1007/PL00000776
  7. 7. Ochs HD, Hollenbaugh D, Aruffo A. The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency. Semin Immunol. 1994; 6:337-41.10.1006/smim.1994.10427532462
  8. 8. Qi CJ, Zheng L, Ma HB, Fei M, Qian KQ, Shen BR, Wu CP, Vihinen M, Zhang XG. A novel mutation in CD40 and its functional characterization. Hum Mutat. 2009; 30:985-94.10.1002/humu.2096719479954
  9. 9. Murugaiyan G, Martin S, Saha B. CD40-induced countercurrent conduits for tumor escape or elimination? Trends Immunol. 2007; 28:467-73.10.1016/j.it.2007.08.01017981086
  10. 10. Farahani M, Treweeke AT, Toh CH, Till KJ, Harris RJ, Cawley JC, Zuzel M, Chen H. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia. 2005; 19:524-30.10.1038/sj.leu.240363115674425
  11. 11. Sabel MS, Yamada M, Kawaguchi Y, Chen FA, Takita H, Bankert RB. CD40 expression on human lung cancer correlates with metastatic spread. Cancer Immunol Immunother 2000;49:101-108.10.1007/s00262005060810823420
  12. 12. Li R, Chen WC, Wang WP, Tian WY, Zhang XG. CD40 signaling activated by agonistic anti-CD40 monoclonal antibody 5C11 has different effects on biological behavior of gastric carcinoma cells. Immunol Lett. 2010; 131:120-5.10.1016/j.imlet.2010.02.00720188757
  13. 13. Kim SW, Lee HS, Yoon SK, Chung WC, Cho YS, Jeong JJ, et al. Expression of CD40 in gastric cancer and its effect on the apoptosis of gastric cancer cells. Korean J Gastroenterol. 2003; 42:274-82.
  14. 14. Tomeczkowski J, Beilken A, Frick D, Wieland B, Konig A, Falk MH, et al. Absence of c-kit receptor and absent proliferative response to stem cell factor in childhood Burkitt’s lymphoma cells. Blood. 1995; 86:1469-80.10.1182/blood.V86.4.1469.bloodjournal8641469
  15. 15. Matsuzawa A, Tseng PH, Vallabhapurapu S, Luo JL, Zhang W, Wang H, et al. Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science. 2008; 321:663-8.10.1126/science.1157340266971918635759
  16. 16. Fang J, Ding M, Yang L, Liu LZ, Jiang BH. PI3K/PTEN/ AKT signaling regulates prostate tumor angiogenesis. Cell Signal. 2007; 19:2487-97.10.1016/j.cellsig.2007.07.025209400417826033
  17. 17. Deregibus MC, Buttiglieri S, Russo S, Bussolati B, Camussi G. CD40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis. J Biol Chem. 2003; 278:18008-14.10.1074/jbc.M30071120012637493
  18. 18. Shafee N, Kaluz S, Ru N, Stanbridge EJ. PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. Cancer Lett. 2009; 282:109-15.10.1016/j.canlet.2009.03.004270628519342157
  19. 19. Edelmann J, Klein-Hitpass L, Carpinteiro A, Fuhrer A, Sellmann L, Stilgenbauer S, et al. Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells. Leuk Res. 2008; 32:1565-72.10.1016/j.leukres.2008.03.00318407351
  20. 20. Schnell CR, Stauffer F, Allegrini PR, O’Reilly T, McSheehy PM, Dartois C, et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res. 2008; 68:6598-607.10.1158/0008-5472.CAN-08-104418701483
  21. 21. Kang J, Rychahou PG, Ishola TA, Mourot JM, Evers BM, Chung DH. N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. Oncogene. 2008; 27:3999-4007.10.1038/onc.2008.15261429018278068
  22. 22. Yuan TL, Choi HS, Matsui A, Benes C, Lifshits E, Luo J, et al. Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc Natl Acad Sci USA. 2008; 105:9739-44.10.1073/pnas.0804123105245307018621722
  23. 23. Dormond O, Contreras AG, Meijer E, Datta D, Flynn E, Pal S, et al. CD40-induced signaling in human endothelial cells results in mTORC2- and Aktdependent expression of vascular endothelial growth factor in vitro and in vivo. J Immunol. 2008; 181: 8088-95.10.4049/jimmunol.181.11.8088349598319018001
  24. 24. Santos SC, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood. 2004; 103:3883-9.10.1182/blood-2003-05-163414726393
DOI: https://doi.org/10.2478/abm-2010-0104 | Journal eISSN: 1875-855X | Journal ISSN: 1905-7415
Language: English
Page range: 797 - 802
Published on: Apr 13, 2018
Published by: Chulalongkorn University
In partnership with: Paradigm Publishing Services
Publication frequency: 6 issues per year

© 2018 Yongling Ning, Keqing Qian, Chunjian Qi, published by Chulalongkorn University
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.